Molecular Testing in Stage 3 Melanoma

Molecular Testing in Stage 3 Melanoma

Publication date: Sep 28, 2018

Merrick I. Ross, MD, discusses the importance of molecular testing in patients with melanoma who are eligible for adjuvant therapy, specifically commenting on the significance of BRAF testing.



Please signin to view all article content and metadata.


Leave a Comment

Your email address will not be published. Required fields are marked *